Xylazine-Induced Respiratory Depression, Potential Additive Effects with Fentanyl, and Potential Treatments

Fentanyl has become increasingly prevalent in the illicit drug supply, exacerbating the opioid overdose crisis. The recent emergence of xylazine has raised concerns of increased overdose risks associated with fentanyl—a potent synthetic opioid that induces severe respiratory depression. Xylazine, canonically known as an alpha-2 adrenergic receptor agonist, may exacerbate respiratory depression and demonstrate resistance to naloxone–an opioid receptor antagonist–reversal due to its known pharmacology. This study examined the respiratory effects of fentanyl and xylazine in Swiss Webster mice using whole-body plethysmography. Dose-dependent respiratory depression was observed across measures, with higher doses exhibiting increased respiratory suppression. The combination of fentanyl and xylazine resulted in respiratory depression that was greater than either drug alone, particularly at higher combinatorial doses. Antagonist pretreatment experiments revealed that atipamezole, an alpha-2 adrenergic receptor antagonist, and its combination with naloxone significantly mitigated respiratory depression compared to naloxone alone, which had decreased efficacy in males. The combined antagonists, however, demonstrated slightly increased efficacy in males. These findings highlight the respiratory risks posed by fentanyl-xylazine combinations and emphasize the need for targeted harm reduction strategies, including the potential use of alpha-2 adrenergic receptor antagonists in overdose management.